Drugs / Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04470089 | Feb 2020 → Dec 2021 | acute pharyngitis | Megainpharm GmbH | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07500844 | Feb 2023 → Nov 2025 | periodontal disorder | Research Centre for Medical Genetics, Russian Federation | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05561816 Comparator | Jul → Nov 2022 | pyoderma | Valenta Pharm JSC | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05561816 ↗ |
| Known as | Dt 2 (surfactant) | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650936 ↗ |
| Known as | Miramistin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07500844 ↗ |
| Known as | Myramistin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04470089 ↗ |
| Modality | Small molecule | — CHEMBL4650936 ↗ |
| Route | Other | “Oromucosal application” NCT04470089 ↗ |